Coagulation factor XIII activity predicts left ventricular remodelling after acute myocardial infarction.
Blood coagulation factor XIII
Cardiac magnetic resonance imaging
Healing and remodelling processes
ST-elevation myocardial infarction
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
09
12
2019
revised:
21
04
2020
accepted:
07
05
2020
pubmed:
18
6
2020
medline:
22
6
2021
entrez:
18
6
2020
Statut:
ppublish
Résumé
Acute myocardial infarction (MI) is the major cause of chronic heart failure. The activity of blood coagulation factor XIII (FXIIIa) plays an important role in rodents as a healing factor after MI, whereas its role in healing and remodelling processes in humans remains unclear. We prospectively evaluated the relevance of FXIIIa after acute MI as a potential early prognostic marker for adequate healing. This monocentric prospective cohort study investigated cardiac remodelling in patients with ST-elevation MI and followed them up for 1 year. Serum FXIIIa was serially assessed during the first 9 days after MI and after 2, 6, and 12 months. Cardiac magnetic resonance imaging was performed within 4 days after MI (Scan 1), after 7 to 9 days (Scan 2), and after 12 months (Scan 3). The FXIII valine-to-leucine (V34L) single-nucleotide polymorphism rs5985 was genotyped. One hundred forty-six patients were investigated (mean age 58 ± 11 years, 13% women). Median FXIIIa was 118% (quartiles, 102-132%) and dropped to a trough on the second day after MI: 109% (98-109%; P < 0.001). FXIIIa recovered slowly over time, reaching the baseline level after 2 to 6 months and surpassed baseline levels only after 12 months: 124% (110-142%). The development of FXIIIa after MI was independent of the genotype. FXIIIa on Day 2 was strongly and inversely associated with the relative size of MI in Scan 1 (Spearman's ρ = -0.31; P = 0.01) and Scan 3 (ρ = -0.39; P < 0.01) and positively associated with left ventricular ejection fraction: ρ = 0.32 (P < 0.01) and ρ = 0.24 (P = 0.04), respectively. FXIII activity after MI is highly dynamic, exhibiting a significant decline in the early healing period, with reconstitution 6 months later. Depressed FXIIIa early after MI predicted a greater size of MI and lower left ventricular ejection fraction after 1 year. The clinical relevance of these findings awaits to be tested in a randomized trial.
Identifiants
pubmed: 32548915
doi: 10.1002/ehf2.12774
pmc: PMC7524135
doi:
Substances chimiques
Factor XIII
9013-56-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2354-2364Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01ES0816
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01ES01901
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01ES01902
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01EO1004
Pays : International
Informations de copyright
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
Références
Mol Med. 2007 Jan-Feb;13(1-2):112-20
pubmed: 17515963
Thromb Res. 2012 Mar;129(3):382-7
pubmed: 22197181
ESC Heart Fail. 2020 Oct;7(5):2354-2364
pubmed: 32548915
Blood. 2008 Feb 1;111(3):1282-6
pubmed: 18006701
Circulation. 1993 Mar;87(3):755-63
pubmed: 8443896
Circulation. 2006 Mar 7;113(9):1196-202
pubmed: 16505171
Circulation. 1986 Oct;74(4):693-702
pubmed: 3757183
Eur Heart J. 2013 Nov;34(42):3314-21
pubmed: 23242190
Haemophilia. 2008 Nov;14(6):1190-200
pubmed: 19141159
Thromb Haemost. 2000 Oct;84(4):595-600
pubmed: 11057856
Eur Heart J. 2008 Feb;29(4):445-54
pubmed: 18276618
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Circulation. 2004 Aug 3;110(5):588-636
pubmed: 15289388
J Am Coll Cardiol. 2002 Sep 18;40(6):1160-7; discussion 1168-71
pubmed: 12354444
Circulation. 1991 Nov;84(5):2123-34
pubmed: 1934383
AJR Am J Roentgenol. 1998 Apr;170(4):889-93
pubmed: 9530028
Blood Rev. 2016 Nov;30(6):461-475
pubmed: 27344554
Blood. 2002 Aug 1;100(3):743-54
pubmed: 12130481
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Thromb Haemost. 2015 Jul;114(1):123-32
pubmed: 25947356
Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H981-3
pubmed: 15706047
Int J Mol Sci. 2018 Sep 14;19(9):
pubmed: 30223472
Wound Repair Regen. 2004 Sep-Oct;12(5):512-7
pubmed: 15453833
Cardiovasc Res. 2005 Apr 1;66(1):22-32
pubmed: 15769445
Biophys Chem. 2004 Dec 20;112(2-3):223-8
pubmed: 15572253
PLoS One. 2006 Dec 20;1:e48
pubmed: 17183677
Prog Cardiovasc Dis. 1987 Sep-Oct;30(2):73-110
pubmed: 2888158
J Am Coll Cardiol. 2016 Mar 15;67(10):1235-1250
pubmed: 26498666
Circulation. 1994 Jul;90(1):411-20
pubmed: 8026026
Cardiovasc Res. 2009 Feb 15;81(3):474-81
pubmed: 18977766
Eur J Heart Fail. 2010 Jul;12(7):753-62
pubmed: 20494925
Transfus Med Hemother. 2012 Apr;39(2):104-113
pubmed: 22670128
Science. 1943 Feb 5;97(2510):137-8
pubmed: 17788516
Br J Clin Pract. 1968 Dec 12;22(12):501-4
pubmed: 4882504